Patent intelligence · US
US 8293720
Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR a…
Patent details — US 8293720
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 23, 2012
- Expiration
- Oct 18, 2032
- Applicant
- Dogwood Pharmaceuticals, Inc.
- Claims
- 30
- CPC classes
- A61K, A61K49/0002, A61K49/0004, A61P
Quick answer
US 8293720 (Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists) is held by Dogwood Pharmaceuticals, Inc.. Status: granted. Granted Oct 23, 2012. Expires Oct 18, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Dogwood Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 30
- CPC classes
- A61K, A61K49/0002, A61K49/0004, A61P, A61P1/00, A61P1/08
More from Dogwood Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 9446021
Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
granted -
US 9120754
Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
granted -
US 8349848
Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors
granted -
US 8263762
Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as A2AR agonists
granted -
US 8258142
Substituted 8-[6-amino-3-pyridyl]xanthines
granted -
US 8252767
Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
granted
Frequently asked questions
What is US patent 8293720?
US 8293720 (Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists) is held by Dogwood Pharmaceuticals, Inc.. Status: granted. Granted Oct 23, 2012. Expires Oct 18, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8293720?
Dogwood Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 8293720 expire?
Our index shows an expiration date of Oct 18, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.